^
    18d
    TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=840, Active, not recruiting, TScan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    1m
    VERSATILE-003: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=351, Active, not recruiting, PDS Biotechnology Corp. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Versamune HPV
    2ms
    QUILT-3.100: IBRX-042 In Participants With HPV-Associated Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Sep 2027
    Enrollment closed • Trial primary completion date
    2ms
    VERSATILE-002: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (clinicaltrials.gov)
    P2, N=95, Completed, PDS Biotechnology Corp. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Versamune HPV
    3ms
    H-200-001: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=198, Completed, Hookipa Biotech GmbH | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    4ms
    Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Weill Medical College of Cornell University
    New P2 trial
    |
    Versamune HPV
    4ms
    Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Anhui Provincial Hospital
    New trial
    |
    HPV-T
    5ms
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Jun 2025 --> Dec 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    bizalimogene ralaplasmid (VGX-3100)
    6ms
    A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Versamune HPV
    7ms
    Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy. (PubMed, J Immunother Cancer)
    Together, these findings provide a rationale for the combination of HPV vaccine, NHS-IL12, and Entinostat in the clinical setting for patients with HPV16-associated malignancies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Jingzhuda (entinostat) • Versamune HPV • PDS01ADC
    7ms
    A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • Versamune HPV
    8ms
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    bizalimogene ralaplasmid (VGX-3100)